Skip to main
FULC

FULC Stock Forecast & Price Target

FULC Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 56%
Sell 22%
Strong Sell 0%

Bulls say

Fulcrum Therapeutics is facing challenges with the discontinuation of its Pociredir program for sickle cell disease due to FDA feedback and concerns around potential risks. However, the company has a strong pipeline of clinical-stage and pre-clinical programs for rare genetic diseases, which could potentially lead to future value creation through strategic alternatives and cost-cutting initiatives. Risks to the company's current outlook include possible setbacks in business development transactions and potential dilution risks in the face of sustained operating expenses.

Bears say

Fulcrum Therapeutics is facing major challenges with their primary product candidate, pociredir, being discontinued due to concerns about the risk of secondary malignancies. This decision by the FDA has greatly impacted the company's future plans and pipeline, forcing them to explore strategic alternatives and undergo restructuring. While the company has a strong cash position, there is limited visibility on future value creation opportunities, and thus a cautious stance is warranted at this time. Additionally, there are various risks to the company, including clinical, regulatory, and financial, which may negatively or positively impact the stock. As a result, a negative outlook is warranted for Fulcrum Therapeutics.

FULC has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulcrum Therapeutics Inc (FULC) Forecast

Analysts have given FULC a Hold based on their latest research and market trends.

According to 9 analysts, FULC has a Hold consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulcrum Therapeutics Inc (FULC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.